We are live on ! Find out more
CRBU icon

Caribou Biosciences

151 hedge funds and large institutions have $343M invested in Caribou Biosciences in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

13% more call options, than puts

Call options by funds: $628K | Put options by funds: $555K

5% more funds holding

Funds holding: 144151 (+7)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 46

5.46% less ownership

Funds ownership: 79.37%73.91% (-5.5%)

15% less capital invested

Capital invested by funds: $402M → $343M (-$59.2M)

Holders
151
Holders Change
+7
Holders Change %
+4.86%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
27
Increased
44
Reduced
46
Closed
20
Calls
$628K
Puts
$555K
Net Calls
+$73K
Net Calls Change
-$152K
Name Holding Trade Value Shares
Change
Change in
Stake
AA
101
Ancora Advisors
Ohio
$103K +$123K +20,000 New
PCM
102
Prelude Capital Management
New York
$101K +$21.4K +3,476 +22%
Simplex Trading
103
Simplex Trading
Illinois
$98K +$11.7K +1,899 +11%
CUAMC
104
China Universal Asset Management Company
China
$87.5K +$41.9K +6,798 +66%
PCIA
105
Prime Capital Investment Advisors
Kansas
$83.8K -$8.42K -1,366 -8%
LP
106
LMR Partners
United Kingdom
$78.2K
VEA
107
Virtus ETF Advisers
New York
$72.2K -$5.93K -961 -6%
HSBC Holdings
108
HSBC Holdings
United Kingdom
$72.1K +$86.5K +14,029 New
EAM
109
Erste Asset Management
Austria
$71.2K
AC
110
AXQ Capital
New Jersey
$70.7K +$84.8K +13,750 New
CC
111
Corton Capital
Ontario, Canada
$70.2K +$5.58K +905 +7%
PA
112
Pinnacle Associates
New York
$66.3K
PWMAG
113
Pinnacle Wealth Management Advisory Group
New Jersey
$66.3K
JF
114
Jump Financial
Illinois
$61.4K +$73.7K +11,954 New
CS
115
Credit Suisse
Switzerland
$57.6K
YIH
116
Y-Intercept (HK)
Hong Kong
$53.4K +$64K +10,385 New
BHCM
117
Brevan Howard Capital Management
Jersey
$52.7K +$63.2K +10,254 New
Victory Capital Management
118
Victory Capital Management
Texas
$52.6K +$63.1K +10,231 New
California State Teachers Retirement System (CalSTRS)
119
California State Teachers Retirement System (CalSTRS)
California
$42.3K -$32.3K -5,242 -39%
NA
120
NewEdge Advisors
Louisiana
$42.1K
AIP
121
Ameritas Investment Partners
Nebraska
$38.5K
Legal & General Group
122
Legal & General Group
United Kingdom
$35.7K
PD
123
Point72 (DIFC)
United Arab Emirates
$31.7K +$38K +6,162 New
MLICM
124
Metropolitan Life Insurance Company (MetLife)
New York
$23.9K +$993 +161 +4%
TRCT
125
Tower Research Capital (TRC)
New York
$22.8K -$102K -16,507 -79%

CRBU Hedge Fund Activity: Q1 2024 in Review

151 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2024, worth a combined $343M — down 15% from $402M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRBU positions and 20 closed out — a net gain of 7 holders — while 44 added to existing stakes and 46 trimmed.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $11.4M. The largest seller was Assenagon Asset Management, cutting an estimated $13.8M.

  • 151 institutional investors held Caribou Biosciences (CRBU) as of Q1 2024, up from 144 in Q4 2023.
  • Funds reported $343M of Caribou Biosciences stock for Q1 2024, down 15% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q1 2024 and 20 closed out, a net change of +7 holders.
  • The largest Caribou Biosciences buyer in Q1 2024 was Schonfeld Strategic Advisors, an estimated $11.4M added.
  • The largest Caribou Biosciences seller in Q1 2024 was Assenagon Asset Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2024.